ICAD (iCAD Corp) קצב צמיחת רווח למניה בשנה הנוכחית

iCAD, Inc. (ICAD) maintains a stable operational foundation driven by the humanitarian status of AI diagnostics and minimal geopolitical risks. However, the company faces pressure from software commoditization and intense market competition. A comparison of annual EPS growth demonstrates valuation dynamics, with the value fixed at 10.00. The business relies on the implementation of automated mammography screening in hospitals and radiology centers.

iCAD, Inc. (ICAD) leadership in AI cancer diagnostics via the ProFound AI system translates directly into financial efficiency. This metric measures the percentage change in net earnings per share compared to the previous year, reflecting the real-time dynamics of monetizing its technological advantage. Analyzing the relative annual growth in earnings per share allows investors to assess the business scaling speed and the issuer's fundamental value.